Social Determinants of Health Research Center, Health Management and Safety Promotion Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Student Research Committee, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Subst Abuse Treat Prev Policy. 2020 Aug 24;15(1):64. doi: 10.1186/s13011-020-00306-1.
Hepatitis C diagnosis could be a gateway to behavioral change and subsequent decline in transmission among people who inject drugs (PWIDs). We assessed the association between the social determinants of PWID, their risk behaviors and hepatitis C testing.
We searched for studies in English published before May 1, 2020, on PubMed, Scopus, Cochrane, and Web of Science to identify primary studies on the factors associated with hepatitis C virus (HCV) testing among PWID. After reviewing for study duplicates, the full-text of selected articles were assessed for eligibility using Population, Intervention, Comparator, Outcomes (PICO) criteria. i) population: individuals who report injecting drugs; ii) intervention: HCV testing in the past year; iii) comparator: PWIDs who did not have an HCV test; iv) outcome: HCV testing among PWIDs and v) study type: cross-sectional, cohort, and case-control studies. Two independent reviewers (author BA and AB) chose the references in a two-phased monitoring process. The authors gathered data from selected papers, including the surname of the first author, publication date, participant demographic data (age, sex, and level of education) and other characteristics like previous HCV testing, past treatment attempts, duration of injecting drug use and condomless sex. We used fixed and random-effects meta-analysis models to estimate the pooled prevalence, pooled odds ratio (OR), and 95% confidence intervals. The data were analyzed using Stata 12.0 software.
After a detailed assessment of over 12,000 articles, a total of 16 studies containing 38,952 participants met the eligibility criteria. Our findings showed a pooled prevalence rate of 61.01% (95% CI, 34.65-84.32%) for recent HCV testing among PWIDs. Being female (OR = 1.69, 95%CI = 1.13, 2.26), aged > 30 years, (OR = 2.61, 95%CI = 1.66-3.56) having past treatment attempt (OR = 2.24, 95%CI = 1.80-2.68), and reporting a previous test (OR = 2.03, 95%CI = 1.23-2.82). were significantly associated with having a recent HCV test.,,. Finding of present study was that unprotected sex had a negative association with HCV testing. Those PWIDs who had unprotected sex were 0.56 times less likely to have completed HCV testing during last year (OR = 0.56, 95%CI = 0.33-0.78).
Prevention programs that address age > 30 years, being female, past treatment attempt, previous testing of safe sexual practices, are strongly recommended to prioritize HCV risk reduction strategies.
丙型肝炎的诊断可能成为行为改变的切入点,并随后降低注射吸毒者(PWID)中的传播。我们评估了 PWID 的社会决定因素、他们的风险行为与丙型肝炎检测之间的关联。
我们在 PubMed、Scopus、Cochrane 和 Web of Science 上搜索了截至 2020 年 5 月 1 日之前发表的英文研究,以确定有关 PWID 中丙型肝炎病毒(HCV)检测相关因素的初步研究。在对研究进行重复审查后,使用人群、干预、比较、结局(PICO)标准对选定文章的全文进行了资格评估。i)人群:报告注射吸毒的个体;ii)干预:过去一年中的 HCV 检测;iii)比较:未进行 HCV 检测的 PWID;iv)结局:PWID 中的 HCV 检测;v)研究类型:横断面、队列和病例对照研究。两名独立的审查员(作者 BA 和 AB)在两个阶段监测过程中选择参考文献。作者从选定的论文中收集数据,包括第一作者的姓氏、出版日期、参与者的人口统计学数据(年龄、性别和教育程度)以及其他特征,如之前的 HCV 检测、过去的治疗尝试、注射吸毒的持续时间和无保护的性行为。我们使用固定效应和随机效应荟萃分析模型来估计汇总患病率、汇总优势比(OR)和 95%置信区间。使用 Stata 12.0 软件进行数据分析。
在详细评估了超过 12000 篇文章后,共有 16 项研究包含 38952 名参与者符合入选标准。我们的研究结果表明,PWID 中最近 HCV 检测的汇总患病率为 61.01%(95%CI,34.65-84.32%)。女性(OR=1.69,95%CI=1.13-2.26)、年龄>30 岁(OR=2.61,95%CI=1.66-3.56)、有过去的治疗尝试(OR=2.24,95%CI=1.80-2.68)和报告之前的检测(OR=2.03,95%CI=1.23-2.82)与最近的 HCV 检测显著相关。未保护的性行为与 HCV 检测呈负相关。过去一年中,有过无保护性行为的 PWID 完成 HCV 检测的可能性降低了 0.56 倍(OR=0.56,95%CI=0.33-0.78)。
强烈建议针对年龄>30 岁、女性、过去的治疗尝试、之前的安全性行为检测等因素制定预防计划,以优先实施 HCV 降低风险策略。